— Lovell is an authorized supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) —
— More than 28,000 cases of multiple sclerosis (MS) are reported to the Department of Veterans Affairs each year —
NEWTOWN, Pa., April 3, 2024 (Globe Newswire) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”) is developing a novel neuromodulatory treatment approach for balance. A neurotechnology company focused on providing The Company today partnered with Lovell Government Services (“Labelle”), an SBA-certified Disabled Veteran-Owned Small Business (“SDVOSB”), to introduce its Portable Neuromodulation Stimulator (“PoNS®”) device. announced that it is now available. to the federal health care system. In the United States, PoNS has been shown to be used as a short-term treatment for gait disturbance in adults with mild to moderate symptoms of MS when combined with physical therapy.
“Through the Multiple Sclerosis Center of Excellence, the Veterans Administration is dedicated to maximizing the quality of life for veterans suffering from MS, and we are partnering with the label to expand the range of innovative PoNS devices. We are excited to expand. In a real-world results study, 100% of MS patients experienced clinically meaningful improvement in gait after 14 weeks of PoNS therapy. More than 28,000 MS cases each year Reported to the Veterans Administration, PoNS can be a game-changer for veterans and their families,” said Helius President and CEO Dane Andreef.
“As the largest integrated health care system in the United States, VA serves veterans with MS from the time of diagnosis through the rest of their lives. People should have access to innovative and effective resources, and Labelle is proud to introduce this important product to the Veterans Administration and other federal health care providers,” said CEO of Labelle Government Services, USMC. said Major (Ret.) Chris Lovell.
“Recently, Helius highlighted the true story of Kevin Byrne, a military veteran who has been suffering from MS since 1999. His difficulty walking deprived him of quality adventures with his most precious treasure, his 13-year-old daughter. Although deprived, PoNS therapy helped improve his gait by increasing speed, endurance, and distance. After treatment with PoNS, he was able to take his daughter to New York City and I enjoyed walking around the city and watching Broadway shows there, but thought I had lost those experiences forever.Clinical results prove the effectiveness of PoNS therapy, but the most satisfying What can be done is first-hand reports like Captain Byrne's,” Andreef concluded.
About Lovell® Government Services
Lovell Government Services has been a trusted SDVOSB vendor since 2013 and has a proven track record of introducing suppliers to the government market. Mr. Lovell is an Inc. 5000 winner twice and is a leader in the federal field. They partner with medical and pharmaceutical companies seeking to better serve veteran and military patients, increase federal revenue streams, and win government contracts. For more information, please visit www.lovellgov.com.
About Helius Medical Technologies, Inc.
Helius Medical Technologies focuses on neurological disorders with an orally applied technology platform that amplifies the brain's ability to engage physiological compensatory mechanisms and promote neuroplasticity, improving the lives of people dealing with neurological diseases. A leading neurotechnology company in the medical device field. The company's first product is a portable neuromodulation stimulator. For more information about PoNS® or Helius Medical Technologies, please visit www.heliusmedical.com.
About PoNS devices and PoNS therapy
Portable Neuromodulation Stimulator (“PoNS”) is an innovative, non-implantable, orally applied therapy that delivers neurostimulation via a mouthpiece connected to a controller to improve balance and gait, primarily at home. Used in conjunction with physical rehabilitation exercises. The PoNS device, which delivers gentle electrical impulses to the tongue, is indicated for use in the United States as a short-term treatment for gait disturbances due to mild to moderate symptoms of multiple sclerosis (“MS”) and will not be used in the future. It is scheduled to be done. For use in patients 22 years of age and older, by prescription only, and as an adjunct to a supervised therapeutic exercise program.
PoNS has been shown to be effective in treating gait and balance in Canada, significantly reducing the risk of falls in stroke patients, and is approved for sale in three indications: (i) Use as a short-term treatment (14 weeks). Walking impairment due to mild and moderate symptoms of stroke. Must be used in conjunction with physical therapy. (ii) used as a short-term treatment (14 weeks) for chronic balance disorders due to mild to moderate traumatic brain injury (“mmTBI”), in conjunction with physical therapy; (iii) used as a short-term treatment (14 weeks) for gait disturbances due to mild and moderate symptoms of MS, in combination with physical therapy; PoNS is also approved for sale in Australia for short-term use by medical professionals as an adjunct to therapeutic exercise programs to improve balance and gait. For more information, please visit www.ponstherapy.com.
Disclaimer Note
Certain statements in this news release are not based on historical fact and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact contained in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as “believes,” “expects,” “continues,” “intends,” “goals,” “objectives” and similar expressions. Such forward-looking statements include, among other things, statements regarding our partnership with Label, the use and effectiveness of PoNS and PoNS therapy.
There can be no assurance that such statements will prove to be accurate or actual results, and future events may differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from our expectations include our capital requirements to achieve our business objectives, the availability of financing, our ability to find additional sources of financing, manufacturing, These include uncertainties related to labor shortages and supply chain risks. , our ability to obtain national Medicare coverage and reimbursement codes, our ability to continue to build out our internal commercial infrastructure, secure state distribution licenses and market awareness of our PoNS devices, including risks associated with manufacturing delays; , in the “Risk Factors” section of the Company's annual report regarding future clinical trials and clinical development processes, product development processes and FDA regulatory submission review and approval processes, other development activities, ongoing government regulations, and forms. and other risks detailed from time to time. Our 10-K and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulators for the year ended December 31, 2023 are available at www.sec.gov or www.sedar.com.
Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company does not intend to update any forward-looking statements or confirm that actual results will change, except as follows: We undertake no obligation to update or update the reasons why such statements may differ. Required by law.
Investor information contact information
Lisa M. Wilson, In-Site Communications, Inc.
Phone: 212-452-2793
E: lwilson@insitecony.com
